Although the analysis of transcriptomic profiles alone is not enough to permit definitive conclusions on the overall effects of CD157-mediated EOC aggressiveness, however, its consistency with the experimental data and clinical observations strongly support the view that CD157 is directly implicated in the control of ovarian cancer progression. The gene discussed is BST1; the disease is ovarian carcinoma.